NEW YORK (GenomeWeb) – Becton Dickinson said today that its BD Max MDR-TB panel has received CE-IVD status and is now available in Europe.

The PCR-based panel is intended to help detect tuberculosis-causing bacteria and determine if the bacteria contains mutations associated with resistance to isoniazid and rifampicin, two important first-line TB drugs.

The assay runs on the BD Max system, a fully integrated and automated molecular diagnostics platform that can run up to 24 samples across multiple tests and provides results for most assays in less than three hours.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Feb
26
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease.